Fulcrum Therapeutics(FULC)
Focus: Fulcrum Therapeutics is a public biotech company focused on unlocking gene control mechanisms to develop small molecule therapies, primarily targeting rare diseases, hematology, and infectious diseases. The company operates at mid-cap scale with a Cambridge, MA base and maintains a lean R&D-focused operation.
Profile data last refreshed 15h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Total Funding
$150M
Open Jobs
3+1 this month
Stable — net +1 jobs in 30d
3 added, 2 removed. Backfill posture.
Should You Work at Fulcrum Therapeutics?
AI assessmentFulcrum offers high scientific impact and early-stage upside for pipeline-focused roles, but limited hiring and tight cash runway make it a bet on clinical catalysts rather than stability.
Why Work Here
- Early-stage pipeline with multiple shots on goal: 11 active trials spanning Phase 1-3, including Phase 3 losmapimod for FSHD and a COVID-19 indication
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Mid-stage
2 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$80M
Pipeline & Clinical Trials
FTX-6058/placebo oral capsule
Healthy Adult SubjectsClinical Trials (1)
NCT04586985Safety, Tolerability and Pharmacokinetics of FTX-6058
Phase 1Help build intelligence for Fulcrum Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.